Alium

Оne of the largest Russian pharmaceutical holdings in the commercial segment.
Effective
shareholding

26.3 percent

revenue
in 2019

7.6 bn ₽

product
portfolio

~200 medicines

production
facilities

4 plants

Development Strategy

Alium is Sistema’s pharmaceuticals holding, being created through the merger of Binnopharm, a pharmaceuticals company established by Sistema in 2006, and OBL Pharm, one of the leading Russian pharmaceutical companies. OBL Pharm is an asset Sistema acquired in 2019 as a part of an investment consortium that includes management of OBL Pharm, VTB, Russian Direct Investment Fund (RDIF), Russian-Chinese Investment Funds (RCIF) and a number of leading investments funds from Middle East.

The deal was aimed to create a leading pharmaceutical group and a top-5 player in the Russian market.

Alium’s total production area exceeds 70,000 sq m and includes four high-tech facilities in Moscow and the Moscow region. 

The company's diversified product portfolio comprises approximately 200 drugs used across therapeutic areas including respiratory, nervous and gastrointestinal systems, cardiology, infectious diseases and colds as well as pain relief. 

The team

Dmitry Zubov

Chairman of the Board of Directors

Rustem Muratov

CEO

Business

Binnopharm

Over 30 drugs

are in development.
JSC Binnopharm is one of Russia's largest full-cycle biopharmaceutical companies and the company boasts an in-house R&D division. Binnopharm produces biotechnological drugs, including a hepatitis B vaccine, a line of pulmonology and neurology drugs, infusion solutions, and anti-viral and immunomodulating drugs.

Binnopharm operates Russia's largest GMP facilities for the production of vaccines in ampoules (producing as many as 80 mln ampoules per year) and a unique, fully equipped quality control laboratory.

The target segments of Binnopharm’s portfolio are pulmonology, neurology, antiviral and immunomodulating drugs. Modern production facilities allow the company to produce a wide range of dosage forms, including tablets, capsules, ampoules, suppositories, syringes and solutions.

Binnopharm's production facilities include two pharmaceutical plants: Binnopharm in the Zelenograd district of Moscow and Alium in the Krasnogorsk district of the Moscow region.

The company is focused on expansion in the commercial segment of the market, while maintaining limited sales of hospital products. The strategic goal of Binnopharm is to saturate the Russian market with state-of-the-art, effective and safe genetically engineered biological drugs and generics of high quality. A total of over 30 drugs are in development and are expected to be released in 2019-2021.
Читать полностью 

OBL Pharm

Over 150

prescription and OTC drugs

In 2019, Sistema acquired an equity interest in JSC Pharmaceutical Enterprise Obolenskoe (OBL Pharm). The stake was acquired jointly with VTB Bank and management of OBL Pharm from Alvansa Ltd, which is majority-owned by Gazprombank and UFG Private Equity. Sistema invested a total of RUB 1.83 billion in the acquisition of OBL Pharm. The investment consortium consisting of Sistema, VTB and members of the OBL Pharm management team collectively acquired 95.14% of OBL Pharm for a total investment of RUB 15.5 billion. In April 2019 Russian Direct Investment Fund (RDIF), the Russia-China Investment Fund and leading Middle Eastern funds joined the project having invested over RUB 4 billion. 

OBL Pharm is one of the leading Russian pharmaceutical companies that develops, manufactures and promotes the latest high-quality medications in compliance with GMP and ISO standards. It produces over 150 prescription and OTC drugs in several therapeutic areas: gastroenterology, cardiology, phlebology, pain relief, insomnia, neurology, male health and others. The company's portfolio includes both innovative products and generics.

It has two production facilities in Obolensk in the Moscow region. Production capacity of the new plant opened in 2019 in Obolensk is 120 mln packages: 1.6 bn pills, 120 mln capsules and 15 mln pouches a year, which is three times greater than the capacity of the legacy facility.

Читать полностью 

Learn more on website
Alium